레고켐바이오

Core Technology

  • Next Generation ADC(Antibody-Drug Conjugate) platform technology
  • ConjuALL™ : ADC platform technology utilizing novel linker chemistry combined with site-specific enzymatic conjugation. Which platform provides solutions for Site-specific conjugation, Linker Stability and Efficient payload release which are three major unmet needs in developing superior ADC.

    차세대 ADC

    - Homogeneous ADC: Enzymatic site-specific conjugation enable design of ADC product with defined DAR

    - Linker Stability: Chemically modified linker which is highly stable in blood circulation and maintaining payload to be successfully delivered to target cells.

    - Efficient Toxin Release: Cleavable linker (Beta Glucuronidase)

top button